Paul B Manning bought $163k of TSHA
owner at Taysha Gene Therapies, Inc.. 100,000 shares at an average of $1.63, traded Nov 17, 2023, filed Nov 20, 2023.
Score components
- +12Role10% owner
- +11Trade size$163k at market
- -5Relative to holdingsUnder 1% of holdings (0.6%)
- +8Price context54% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- +10Track recordMedian 6-month excess return +18% over 4 past buys
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -21.1%, 3m +6.1%, 6m +71.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001209191-23-055942, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 17, 2023 | POpen-market purchase Common Stockindirect: See footnote | +100,000 | $1.63 | $163k | 16,566,667 | Nov 20, 2023 |
Related signals
Other insiders at Taysha Gene Therapies, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | Taysha Gene Therapies, Inc. | Sukumar Nagendran President and Head of R&D | $1.2M 200,000 shares | -18% | |
| 13Weak | Taysha Gene Therapies, Inc. | Sukumar Nagendran President and Head of R&D | $892k 200,000 shares | -15% | |
| 37Weak | Taysha Gene Therapies, Inc. | Kamran Alam CHIEF FINANCIAL OFFICER | $7,481 1,655 shares | -0% | |
| 55Moderate | Taysha Gene Therapies, Inc. | Kamran Alam CHIEF FINANCIAL OFFICER | $485k 102,817 shares | -7% | |
| 54Moderate | Taysha Gene Therapies, Inc. | Sukumar Nagendran President and Head of R&D | $547k 116,050 shares | -8% | |
| 63Notable | Taysha Gene Therapies, Inc. | Sean P. Nolan Chief Executive Officer | $840k 178,101 shares | -6% | |
| 29Weak | Taysha Gene Therapies, Inc. | Sukumar Nagendran President and Head of R&D | $942k 200,000 shares | -17% | |
| 40Moderate | TSHAsell Taysha Gene Therapies, Inc. | Sukumar Nagendran President and Head of R&D | $1.7M 370,172 shares | -33% | |
| 10Weak | Taysha Gene Therapies, Inc. | Sukumar Nagendran President and Head of R&D | $646k 200,000 shares | -17% | |
| 41Moderate | Taysha Gene Therapies, Inc. | Kamran Alam CHIEF FINANCIAL OFFICER | $155k 54,491 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.